Case report demonstrates the value of FDOPA PET in pediatric anaplastic pleomorphic xanthoastrocytoma, indicating metabolic response detection precedes conventional imaging.
Anaplastic pleomorphic xanthoastrocytoma (APXA) is a rare pediatric high-grade glioma (pHGG). We report a 10-year-old boy with a left temporal APXA harboring a BRAF V600E mutation, who presented with generalized tonic–clonic seizures 3–4 times weekly, treated with combined BRAF and MEK inhibition. This case illustrates the utility of [ 18 F]FDOPA PET in monitoring targeted therapy, providing metabolic information that preceded and complemented conventional imaging.
No takes yet. Share an insight, caveat, or question.
Passoni et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: